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Clinical manifestations of lactase (LCT) deficiency include intestinal and extra-intestinal symptoms. Lactose hydrogen breath test (H2-BT) is
considered the gold standard to evaluate LCT deficiency (LD). Recently, the single-nucleotide polymorphism C/T213 910 has been associated
with LD. The objectives of the present study were to evaluate the agreement between genetic testing of LCT C/T213 910 and lactose H2-BT,
and the diagnostic value of extended symptom assessment. Of the 201 patients included in the study, 194 (139 females; mean age 38, range
17–79 years, and 55 males, mean age 38, range 18–68 years) patients with clinical suspicion of LD underwent a 3–4 h H2-BT and genetic testing
for LCT C/T213 910. Patients rated five intestinal and four extra-intestinal symptoms during the H2-BT and then at home for the following 48 h.
Declaring H2-BT as the gold standard, the CC213 910 genotype had a sensitivity of 97 % and a specificity of 95 % with a k of 0·9 in diagnosing LCT
deficiency. Patients with LD had more intense intestinal symptoms 4 h following the lactose challenge included in the H2-BT. We found no differ-
ence in the intensity of extra-intestinal symptoms between patients with and without LD. Symptom assessment yielded differences for intestinal
symptoms abdominal pain, bloating, borborygmi and diarrhoea between 120 min and 4 h after oral lactose challenge. Extra-intestinal symptoms
(dizziness, headache and myalgia) and extension of symptom assessment up to 48 h did not consistently show different results. In conclusion,
genetic testing has an excellent agreement with the standard lactose H2-BT, and it may replace breath testing for the diagnosis of LD. Extended
symptom scores and assessment of extra-intestinal symptoms have limited diagnostic value in the evaluation of LD.
CT213 910: Genetic testing: Lactose intolerance: Lactase deficiency: H2-breath test: Hypolactasia: Abdominal pain: Bloating: Diarrhoea
Worldwide, over 5 billion humans are estimated to suffer from
lactase (LCT) deficiency, which is the most common cause of
lactose intolerance. The geographical distribution of lactose
intolerance is variable depending mostly on heritage: in
Asian countries, close to 100 % of the general population is
considered lactose intolerant, whereas in Northern Europe,
prevalence reaches about 10–20 % increasing towards the
south(1). Lactose is a disaccharide physiologically cleaved
into glucose and galactose by LCT located on the luminal
membrane of the enterocytes located in the proximal small
bowel. Reduced expression and/or activity of LCT leads to an
accelerated intestinal transit and degradation of lactose by
colonic bacteria into SCFA, H2 and other metabolites impli-
cated in the pathophysiology of classical abdominal symptoms
such as diarrhoea, bloating, borborygmi and abdominal pain.
Most laboratories employ a lactose H2-breath test (H2-BT)
in diagnosing LCT deficiency (LD). This test exploits the
fact that H2, a by-product of bacterial lactose metabolism,
is absorbed through the intestinal mucosa into the venous
blood, and transported past the liver into the alveoli of the
lungs, from where it is exhaled(2,3). Several studies correlating
the amount of exhaled H2 with LCT deficiency documented
a good sensitivity (76–94 %) and specificity (77–96 %) of
the BT(2).
In 2002, Enattah et al.(4) described single-nucleotide poly-
morphism 13 910 bp above the structural gene coding for the
enzyme LCT on the short arm of chromosome 2q.21-22.
This polymorphism consists of the nucleotide switch of T
for C, resulting in variants CC, CT or TT213 910. Enattah
demonstrated CC213 910 to be a good predictor of intestinal
LCT activity loss. A recent study(5) showed a lower sensitivity
of genetic testing of only 75 % when compared with H2-breath
testing based on ingestion of lactose.Other genetic polymorph-
isms, with the most prominent one being G/A222 018 identified
in European and Asian subjects, have also been shown to be
of importance, but they have not been commercially marketed
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to date(4). Recently, polymorphisms especially in the sub-
Saharan African population have demonstrated local gene
traits(6). Genetic tests fail to detect secondary causes of rela-
tive LCT deficiency such as inflammatory or malabsorptive
bowel disease, in which reduced mucosal absorptive area,
insufficient contact time between substrate and enzyme, and
also reduced mucosal expression of LCT lead to incomplete
degradation of lactose(7). Besides classical symptoms of
lactose intolerance, extra-intestinal symptoms such as head-
ache, fatigue and muscle pain have been suggested to occur
in response to ingestion of LCT(8 – 10).
The aims of the present study were (1) to compare the
results of H2-BT against those of the genetic test; (2) to
evaluate the utility of collecting data on intestinal and extra-
intestinal symptoms for up to 48 h after oral ingestion of
lactose.
Methods
Patients
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki. All study subjects
provided written informed consent before being enrolled in
the present study. The study was approved by the Ethics
Committee of the University Hospital Zurich and of the
Canton of Zurich (EK-1225). Consecutive patients referred
to our tertiary referral centre for suspected lactose intolerance
were included in the study. Subjects were required to be at
least 16 years old. Patients with antibiotic use in the past
2 weeks before the procedure, with active chronic or acute
inflammatory bowel disease and with drug or alcohol abuse
were excluded from the study.
Lactose hydrogen breath test
To minimise basal H2 values, patients were instructed to
consume a carbohydrate-deficient diet (especially avoiding
beans, soya products, lentil, peas and whole-grain breads)
1 week before the testing, and to fast at least 12 h before the
test. Smoking and physical activity were to be avoided at
least 1 h before the test and during the entire test procedure.
The oral cavity was decontaminated with 2 £ 20 ml of Hextril
solution (Pfizer, Zurich, Switzerland). End-expiratory H2
values were measured offline using a stationary H2 detection
system (Acutronic Medical Systems, Hirzel, Switzerland).
For adequate sample collection, patients were instructed to
perform two empty breath manoeuvers before each H2
breath sample collection in order to remove dead air space
in the respiratory tree. Patients then exhaled normally, and
samples were collected mid-expiration using 20 ml plastic
syringes. After determining the baseline H2 concentration,
patients received 50 g lactose powder, or an equivalent of
1 mg/kg body weight was given for patients weighing less
than 50 kg. The lactose powder (Kantonsapotheke Universi-
ta¨tsspital Zu¨rich, Switzerland) was dissolved in 150–200 ml
of water. Mid-expiratory H2 breath samples were collected
every 15 min for 4 h. At each time point, two breath samples
were drawn from each patient, the higher of which was used
for analysis. The collected air samples were analysed within
5 min after collection.
The lactose H2-BT was considered positive (i.e. indicative
of LCT deficiency) if there was a rise of at least 20 ppm
in H2 concentration above baseline in at least two consecutive
measurements, starting minimum 30 min into the test.
Symptom questionnaire
Patients were asked to rate five typical symptoms of
lactose intolerance (nausea, bloating, diarrhoea, borborygmi
and abdominal pain) and four extra-intestinal symptoms
(headache, dizziness, fatigue, and muscle and joint pain) on
a 9-point Likert symptom scale ranging from 1 (non-existent)
to 9 (worst ever). For the duration of the study symptoms,
rating was done every 15 min concomitant with H2 measure-
ments. After this, patients were asked to rate both intes-
tinal and extra-intestinal symptoms every 4 h for 48 h after
the intake of lactose. Patients were asked to omit values
during their sleeping period to avoid any influence of sleep-
disturbance effects on symptom recording. Patients left the
hospital after 4 h, and they were instructed to refrain from
lactose intake (after being given dietary instruction including
hidden lactose) for 48 h. Patients were provided pre-stamped
envelopes to mail the completed symptom questionnaire to
our institute.
Lactulose hydrogen breath test
In patient with discrepant results between genetic test and
H2-BT, a lactulose test was performed either to exclude bac-
terial overgrowth in those with positive H2-BT and negative
genotype (see below), or to exclude H2 non-secretory status
in patients with negative H2-BT and positive genotype
(see below). Pre-test preparation was identical to that of the
lactose BT. Patients were asked to drink 25 g of lactulose
powder dissolved in 150–200 ml water, and mid-expiratory
samples were taken every 15 min for 4 h. The test was con-
sidered positive for bacterial overgrowth when there was a
rise in H2 peak concentration of more than 20 ppm above
baseline at least 15 min before measurement of a colonic
peak of at least 10 ppm above baseline(11). Non-excretion indi-
cating a lack of H2-producing intestinal flora was considered
in patients with a rise not exceeding 10 ppm above baseline.
Genetic testing
Venous blood samples were drawn from patients into EDTA
tubes (Braun, Melsungen, Germany). Blood samples were
stored refrigerated at 48C for a maximum of 5 d before genetic
analysis. Genotyping of the LCT C/T213 910 polymorphism
was done in the diagnostic laboratory of the Institute of
Clinical Chemistry of the University Hospital Zurich using
melting curve analysis on a Roche LightCycler (Rotkreuz,
Switzerland) according to the previously described method
by Stolba et al.(12). Accuracy and robustness of the assay
were evaluated in the laboratory using sequenced control
DNA in repeated experiments.
Statistics
Sensitivity, specificity, and positive and negative predictive
values were calculated between results from H2-BT and
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genetic testing. Agreement was calculated using Cohen’s k.
Symptom intensity was compared using ANOVA with
post hoc Bonferroni’s correction for multiple testing. Differ-
ences were considered statistically significant if P,0·05.
Results
Patient demographics
In the present study, 201 patients were included. Seven
patients who had high basal H2 values or had denied genetic
testing after consenting to the study were excluded from the
analysis. Remaining patients (total 194: 139 females, mean
age 38, range 17–79 years, and 55 males, mean age 38,
range 18–68, P¼0·926) referred for testing of suspected
lactose intolerance underwent a lactose H2-BT and genetic
testing for LCT C/T213 910. Patients were largely Northern
European (154 Northern Swiss and German, and 5 Eastern
Europeans), and furthermore, twenty-six patients were
Southern Europeans (including Southern Switzerland), eight
were of Asian descent (one Chinese and seven Indian)
and seven patients were from Southeast Europe and the
Middle East.
Lactose hydrogen breath test
Of all the patients referred for the evaluation of lactose
intolerance, sixty-three patients (32·5 %) tested positive for
LCT deficiency based on exhaled H2 values after ingestion
of lactose (Table 1). There were no age (P¼0·226)- or sex
(P¼0·865)-specific differences between the patients with
normal LCT activity and LCT deficiency.
Genetic test v. lactose hydrogen breath test
Sixty-eight (35·1 %) patients were CC213 910 homozygotes,
which is the genotype associated with LCT deficiency.
Another sixty-eight (35·1 %) patients were CT213 910 hetero-
zygotes, and fifty-eight (29·9 %) patients were TT213 910
homozygotes indicating normal LCT activity (Table 1).
There was an excellent agreement between the genetic
analysis and the H2-BT with only nine (4·6 %) discrepant
results. Using the lactose H2-BT as the gold standard, only
two patients were misclassified as LCT sufficient (i.e. false
negative) in the genetic test, leading to an excellent sensitivity
and negative predictive value in diagnosing LCT deficiency
(Table 1). Overall, the genetic analysis identified 35·1 % of
the patients as LCT deficient, while the H2-BT identified
32·5 % as LCT deficient.
Discrepant results – lactulose breath test
Of the 194 patients included in the analysis, nine (4·6 %)
patients had discordant results between lactose H2-BT and
genetic analysis. These patients were clinically reassessed,
and eight patients agreed to undergo the lactulose H2-BT.
Table 2 and Fig. 1 show individual patient exam stratification
and results.
Seven of nine (78 %) patients with initially discrepant test
results were CC213 910 homozygotes indicating LCT
deficiency, but they had a negative lactose BT.
Upon focused re-assessment, three patients remembered
having used antibiotics shorter than 4 weeks before the test
(Helicobacter pylori eradication, chronic urinary tract infec-
tion), which could have interfered with the test, leading to a
false-negative H2-breath test. However, when tests were per-
formed 2 and 4 months after the initial lactose breath test,
two of these three patients who underwent a lactulose breath
test exhibited a hydrogen-producing colonic flora, possibly
reflecting restoration of formerly suppressed colonic flora.
Two patients were identified as non-H2 producers by lactulose
BT. One patient had a H2 elevation of more than 20 ppm from
baseline at only one time point, very little symptoms and only
a slight elevation during the lactulose BT. Finally, one patient
had a false-positive genetic test as all other test results spoke
in favour of lactose deficiency: non-significant H2 elevation,
absence of symptoms and a positive lactulose BT indicating
H2-producing flora.
Among the two patients with genotypes indicating normo-
lactasia but abnormal lactose BT, one patient had small intes-
tinal bacterial overgrowth and the other patient had
intercurrent bouts of inflammatory bowel disease resulting in
secondary lactose intolerance.
Symptom analysis – overall interpretation
There were no differences between sexes in symptom distri-
bution (all P.0·05). Patients (both males and females) with
genotype CC213 910 were symptomatic in 75 % of the cases.
Thirty-eight percentage of women were symptomatic with
genotype CT213 910 v. 24 % of men, and 38 % of women
were symptomatic with genotype TT213 910 v. 33 % of men.
Symptom analysis – intestinal symptoms
A completed 48 h symptom questionnaire was available
from 95 % of the patients (185/194). Patients with CC213 910
homozygous genotypes (sixty-four complete symptom sets
available) reported more intense intestinal symptoms (borbor-
ygmi, bloating, abdominal pain and diarrhoea) than patients
with CT213 910 heterozygous genotypes (fifty-five complete
symptom sets available) and TT213 910 homozygous geno-
types (fifty-six complete symptom sets available). Symptoms
became intense 45 min after lactose intake and lasted up
to 12 h. Peak intensity was reached after 4–8 h of lactose
ingestion as indicated in Fig. 2.
There was a fair agreement between symptomatic hydrogen
breath test and CC213 910 genotype (k 0·365, P,0·001). Of the
patients with a positive genetic test, 75 % (fifty-one) with
genotype CC13 910 were considered symptomatic compared
Table 1. Genotype* and lactose hydrogen breath test (H2-BT) results
n 194 CC13 910 CT13 910 TT13 910
H2-BT (þ) 61 (31·4 %) 1 (0·5 %) 1 (0·5 %)
H2-BT (2 ) 7 (3·6 %) 67 (34·5 %) 57 (29·4 %)
* Sensitivity of genotype C/T13 910 compared with H2-BT was 97 %, specificity
was 95 %, positive predictive value was 90 % and negative predictive value
was 98 %. Cohen’s k for agreement was 0·9.
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with 33·8 % (twenty-three) with genotype CT13 910 and 36·2 %
(twenty-one) with genotype TT13 910 (P,0·01).
Symptom analysis – extra-intestinal symptoms
Patients with genotypes indicating LCT deficiency reported
similar intensity of dizziness and muscle and joint pain
compared with those with genotypes indicating normal LCT
activity. Patients with genotype CC reported more intense
fatigue 4–12 h after ingestion of lactose compared with
those with genotype CT/TT. The intensity of extra-intestinal
symptoms are summarised in Fig. 3.
Discussion
In the present study, we have reported on the relationship
between genetic testing and lactose H2-BT in patients evalu-
ated at a Swiss tertiary referral centre. Additionally, in the
present study, we have also reported on the intensity of intes-
tinal and extra-intestinal symptoms characteristic for lactose
intolerance in LCT-deficient and non-deficient individuals.
We found an excellent agreement, sensitivity and specificity
between results from testing for genetic polymorphism LCT
C/T213 910 and lactose H2-BT. In patients with discrepant
results, a careful history and lactulose H2-BT clarified the
diagnosis. With regard to intestinal symptoms, patients with
LCT deficiency reported higher symptom intensity for 2–10 h
after oral ingestion of lactose for all symptoms except for
nausea. LCT-deficient patients and those with normal LCT
activity reported similar intensities of extra-intestinal symp-
toms with the exception of fatigue. Increased fatigue 4–16 h
after oral ingestion of lactose was most likely the result of
the increased intestinal symptoms rather than being directly
related to lactose intolerance.
The present results are consistent with a previous report
by Krawczyk et al.(13) who evaluated fifty-eight patients
for lactose intolerance in a German tertiary referral centre.
They found a 100 % agreement between lactose H2-BT and
genotype CC213 910. Considering the genetic test as the gold
standard, they reported an excellent sensitivity and negative
predictive value of the H2-BT.
Nine patients (4·6 %) in our group had discrepant results in
the lactose H2-BT. The most common reason (33 %) for the
discrepant results was the prior use of antibiotics leading to
suppressed intestinal flora and a ‘non-H2 producer’ status.
Few of our patients had a false-positive result. Colonisation
of the proximal intestinum with H2-producing bacteria termed
small intestinal bacterial overgrowth can lead to false-positive
BT results(14). We diagnosed one patient with small intes-
tinal bacterial overgrowth; the other patient’s positive lactose
H2-BT despite negative genetic test was most likely attri-
butable to intermittent bouts of inflammatory bowel disease,
which was not recognised at study inclusion(7).
Ho¨genauer et al. reported a lower sensitivity (75 % opposed
to 97 % in our subjects) in the detection of LCT deficiency
when comparing genetic test and lactose H2-BT as the gold
standard(5). Differences in test design (in our study patients
had to reach a d H2 peak above 20 ppm in at least two
consecutive measurements) and studied population have to
be taken into account when interpreting these data. Similar
to our findings, Ho¨genauer reported a high specificity inT
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diagnosing LCT deficiency in patients with genotype
CC213 910. One patient with negative lactose H2-BT and
normal lactulose H2-BT had a positive genetic test. This
may be explained by LCT persistence into young adulthood
as shown in a recent two-decade follow-up study in a Finnish
population(15). Furthermore, epigenetic modulation of the
DNA with consecutive changes in functional properties or
gene–gene interactions have to be discussed, and since we
did not test for other genetic polymorphisms possibly associ-
ated with LCT persistence such as G22 018, C214 010, G213 907
and G213 915, we cannot rule them out
(4,16). A second patient
with negative H2-BT, few symptoms and slightly elevated
breath H2 concentrations had a positive genetic test. This
patient was considered a low-H2 producer, but transition into
LCT deficiency as mentioned earlier cannot be excluded. A
technical limitation in the diagnosis of the LCT C/T213 910
genotype has been discussed in systems employing Light-
Cycler diagnosis and melting curve analysis(17). However,
since our population was largely European and five of seven
patients with genotype CC13 910 and negative BT were clearly
symptomatic indicating lactose intolerance, we believe that
this should not affect our diagnoses and derived statements.
Adding to the finding of previous investigators who compared
genetic testing and phenotype, our data show a high negative
predictive value of 98 % for genetic testing, supporting a
low likelihood of LCT deficiency in patients with genotypes
CT and TT13 910.
Symptom analysis is an important part of establishing a
clinical diagnosis of lactose intolerance. Symptoms typically
attributed to lactose intolerance include abdominal pain,
nausea, diarrhoea, bloating and borborygmi. In addition to
these, it has been suggested that systemic extra-intestinal symp-
toms such as headache and light headedness (up to 86 %),
loss of concentration and short-term memory loss (82 %),
fatigue (63 %) and muscle and joint pain (71 %) as well as aller-
gic reactions (40 %, including eczema, pruritus and airway
reaction) could be the results of LCT deficiency(8 – 10). In
addition to the typical intestinal symptoms, we chose four
extra-intestinal symptoms (headache, fatigue, dizziness, and
muscle and joint pain) and a time frame of 48 h to explore
symptoms which may occur late after oral ingestion of lactose.
For typical intestinal symptoms, the results were consis-
tently different for all the symptoms except for nausea.
Patients with genotype indicative of LCT deficiency had
more intense symptoms starting from 45 min (bloating) to
90 min (diarrhoea) and lasting 8 h (abdominal pain) to 28 h
(borborygmi) after oral ingestion of lactose. Roughly one-
third of our patients with lactose persistence had typical
symptoms of lactose intolerance although showing LCT
persistence. Interestingly, one-quarter of the patients without
adequate LCT production remained largely asymptomatic. It
has been shown that there is a considerable overlap between
irritable bowel syndrome and lactose intolerance plus the
placebo effect as patients may have been biased to test posi-
tive for different reasons. On the other hand, it has been
shown that most patients with LCT deficiency do not develop
symptoms after intake of usual servings of lactose (12·5 g as
in one cup of milk)(18). Even the considerably larger dose of
50 g, which is considered adequate in a Northern European
population, only showed a sensitivity of 75 % to detect
194 patients with suspected LD
H2-BT (+) H2-BT (–)
Genotype CC13 910 Genotype CT/TT13 910 Genotype CT/TT13 910 Genotype CC13 910
Lactulose test (+) Lactulose (+) Lactulose (–)
63 131
7124261
SIBO normolactasic Sec. hypolactasia (Crohn)
Hypolactasic Normolactasic
Antibiotic use, symptomatic
Hypolactasic
Non-H2 producer
Hypolactasic
61 2
1 1
124 2
2
4
2
No antibiotic use,
aymptomatic
Normolactasic
Weak H2 lactose and lactulose BT,
few symptoms, probably
transition Normo–Hypolactasic
1 1
Fig. 1. Flowchart showing patient results and stratification. , Diagnosis; , discrepant results. LD, lactase deficiency; H2-BT, hydrogen breath test.
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hypolactasia by symptoms. This underlines the individual
perception of symptoms and may also be caused by a certain
tolerance of larger lactose doses, as portion sizes increase
around the globe(19), and evidence exists that patients with
lactose intolerance can adapt over time to larger doses of
lactose by adaptation of their microflora(20).
There was no difference in symptom expression between
genotypes CT13 910 and TT13 910 at any time point. Conversely
to this, Matthews et al.(10) reported differences in sensitivity of
H2 lactose testing between genotypes CT and TT13 910 in a
large patient population. The reason for this discrepancy is
unclear, and it may be due to patient population as they exam-
ined patients from an irritable bowel syndrome cohort possibly
suffering in part from underlying motility disorder or small
intestinal bacterial overgrowth leading to secondary lactose
intolerance of false-positive results. Furthermore, the authors
performed 6 h H2 recordings, whereas we tested patients for
a maximum of 4 h. Though our time window of symptom
assessment of 48 h was clinically important, in our patient
population clinically suspected to have lactose intolerance in
the first 6 h or later up to 48 h, differences in neither intestinal
symptoms nor extra-intestinal symptoms were noted based on
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Fig. 2. Intestinal symptom scores over 48 h according to genotyping for lactase C/T213 910. (a) Borborygmi, (b) bloating, (c) abdominal pain, (d) diarrhoea and
(e) nausea. , Genotype CC; –O–, genotype CT; –B–, genotype TT. * Mean values were significantly different (P,0·05).
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difference in genotypes CT and TT13 910. Kuokkanen et al.
(21)
noted different levels of intestinal brush border LCT with
4–9 U/g in CC213 910 carriers and with 13–49 and 18–87 U/g
in CT and TT carriers, respectively. We believe that the
observed large overlap in LCT expression between CT and
TT213 910 carriers explains the similar symptom pattern in
patients, and that it does not seem to translate into clinically
significant differences in our patient population. This is in
accordance to the data reported by Ho¨genauer et al.(5),
although they showed a higher percentage of CT-carrying
patients than of TT213 910-carrying patients with lactose
H2-BT indicating LCT deficiency.
Extra-intestinal symptoms did not yield different results
based on genetic testing for LCT deficiency either during the
initial 4 h window, where symptoms were quantified every
15 min, or in the 44 h thereafter. Only fatigue was noted more
often in patients with LCT deficiency 4–16 h after ingestion.
This may be due to a vagal nerve system response due to
increased intestinal activity with respect to the osmotic
challenge by undigested lactose or a reaction to typical
intestinal symptoms during the first hours of the test that may
be painful and stressful in patients with lactose intolerance.
The long duration of classical symptoms was somewhat
surprising, as from a mechanistic standpoint, undigested
lactose passes quicker through the intestine due to its osmotic
properties. This may be explained by two mechanisms.
First, apart from lactose residues still causing mechanical
symptoms, the concept of a local reaction via impairment of
the endoplasmic reticulum in the intestinal wall after provoca-
tion with large amounts of lactose emerged, which may be
comparable to changes induced by viral infections(22). Sec-
ondly, direct effects on the mucosa comparable to those
caused by bacterial enterotoxins have been discussed, but
have not been validated yet(10,23).
In conclusion, our data show that the testing of LCT
C/T213 910 genotype could become the first-line test for inves-
tigating patients with symptoms suggestive of lactose intoler-
ance. The length and self-limitation of symptoms provoked
by a lactose H2-BT are clinically important information to
be shared with the patients, and if needed, pain and/or anti-
spasmodic medication should be provided. Extended symptom
questionnaires do not yield meaningful information on patients
with LCT deficiency.
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